LivaNova's VNS Therapy Reimbursement Increases by 48% Under Medicare
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 24 2025
0mins
Source: Newsfilter
- Reimbursement Increase: LivaNova's VNS Therapy has been assigned to New Technology APC 1580 under Medicare, with new patient implant reimbursements increasing by approximately 48%, significantly improving hospital economics and reducing barriers to procedure penetration.
- Service Upgrade: The end-of-service procedures for VNS Therapy have been elevated from Level 4 to Level 5, which is expected to increase hospital reimbursement rates by 47%, encouraging hospitals to more actively offer this treatment to meet the urgent needs of drug-resistant epilepsy patients.
- Expanded Patient Access: This reimbursement adjustment will significantly enhance access to VNS Therapy, helping more patients, especially those severely underserved in the current healthcare system, to receive treatment.
- Clinical Effectiveness: The CORE-VNS study demonstrated an 80% median reduction in seizure frequency for focal onset motor seizures at 36 months, providing significant quality of life improvements for patients and further driving market acceptance of this therapy.
Get Free Real-Time Notifications for Any Stock
Monitor tickers like LIVN with instant alerts to capture every critical market movement.
Sign up for free to build your custom watchlist and receive professional-grade stock notifications.
Analyst Views on LIVN
Wall Street analysts forecast LIVN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LIVN is 72.50 USD with a low forecast of 64.00 USD and a high forecast of 85.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
8 Analyst Rating
6 Buy
2 Hold
0 Sell
Strong Buy
Current: 63.910
Low
64.00
Averages
72.50
High
85.00
Current: 63.910
Low
64.00
Averages
72.50
High
85.00
About LIVN
LivaNova PLC is a medical technology company. The Company designs, develops, manufactures, markets and sells products and therapies. Its segments include Cardiopulmonary, and Neuromodulation. Its Cardiopulmonary segment is engaged in the design, development, manufacture, marketing, and sale of cardiopulmonary products, including heart-lung machines (HLM), oxygenators, autotransfusion systems, perfusion tubing systems, cannula, and other related accessories. Its Neuromodulation segment is engaged in the design, development, manufacture, marketing, and sale of devices that deliver neuromodulation therapy for treating drug-resistant epilepsy (DRE) and difficult-to-treat depression (DTD). Its principal Neuromodulation product, the VNS Therapy System, consists of an implantable pulse generator and connective lead that stimulates the vagus nerve, surgical equipment to assist with the implant procedure, and equipment and instruction manuals.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Tesla, Microsoft, and Meta Earnings Capture Attention
- Earnings Reports: Tesla, Microsoft, and Meta released their earnings after the stock market reached record highs, yet investor sentiment remains cautious regarding future performance expectations despite the positive results.
- Market Reaction: Following the earnings announcements, the overall market response was muted even though all three companies performed well, indicating investor concerns about sustained high valuations.
- Industry Impact: The earnings reports from these tech giants are likely to significantly influence investment sentiment across the tech sector, potentially leading other companies to adopt more conservative forecasts in their upcoming earnings.
- Investor Strategy: With the earnings releases, investors may reassess their portfolios, particularly in the context of high valuations in tech stocks, which could result in a shift of funds towards more value-oriented assets.
Continue Reading
Tesla, Microsoft, and Meta Report Strong Earnings
- Strong Earnings Reports: Tesla, Microsoft, and Meta released impressive earnings after the stock market reached record highs, showcasing robust revenue growth and profitability, which further solidifies investor confidence in tech stocks.
- Positive Market Reaction: Following the earnings announcements, stock prices for all three companies rose, reflecting market optimism regarding their future growth potential, particularly against the backdrop of a global economic recovery.
- Industry Leadership: Tesla maintains its lead in the electric vehicle market, Microsoft shows strong momentum in cloud computing, and Meta demonstrates significant innovation in social media and virtual reality, enhancing its competitive position in the market.
- Increased Investor Confidence: The release of these earnings not only boosts investor confidence in the tech sector but may also attract more capital into the field, potentially driving further market gains.
Continue Reading